FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kevin Yee

Research Profile

Chemicals & Drugs

Anatomy

Cell Line

Living Beings

Mouse

Physiology

Genes & Molecular Sequences

Amino Acid Sequences

Disorders

Co-author Network

Publications

TOP 3
Marcus Schittenhelm; Kerstin M Kampa; Kevin W H Yee; Michael C Heinrich
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Kevin W H Yee; Marcus Schittenhelm; Anne-Marie O'Farrell; Ajia Town; Laura McGreevey; Troy Bainbridge; Julie M Cherrington; Michael C Heinrich
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kevin Yee (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Marcus Schittenhelm; Kerstin M Kampa; Kevin W H Yee; Michael C Heinrich
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Cell cycle (Georgetown, Tex.) 2009;8(16):2621-30.
2006: Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Leukemia 2006;20(11):2008-14.
2004: Kevin W H Yee; Marcus Schittenhelm; Anne-Marie O'Farrell; Ajia Town; Laura McGreevey; Troy Bainbridge; Julie M Cherrington; Michael C Heinrich
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood 2004;104(13):4202-9.
2004: Amie S Corbin; Ian J Griswold; Paul La Rosée; Kevin W H Yee; Michael C Heinrich; Corinne L Reimer; Brian J Druker; Michael W N Deininger
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Blood 2004;104(12):3754-7.
2003: Aviv Gazit; Kevin W H Yee; Andrea Uecker; Frank-D Böhmer; Tobias Sjöblom; Arne Ostman; Johannes Waltenberger; Gershon Golomb; Shmuel Banai; Michael C Heinrich; Alexander Levitzki
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.
Bioorganic & medicinal chemistry 2003;11(9):2007-18.
2003: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
2002: Kevin W H Yee; Anne-Marie O'Farrell; Beverly D Smolich; Julie M Cherrington; Gerald McMahon; Cecily L Wait; Laura McGreevey; Diana J Griffith; Michael C Heinrich
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Blood 2002;100(8):2941-9.
2002: Kevin W H Yee; Brett C Sheppard; John S Domreis; Charles D Blanke
Cancers of the gallbladder and biliary ducts.
Oncology (Williston Park, N.Y.) 2002;16(7):939-46, 949; discussion 949-50, 952-3, 956-7.
1993: Kevin W H Yee; T R Bishop; C Mather; L I Zon
Isolation of a novel receptor tyrosine kinase cDNA expressed by developing erythroid progenitors.
Blood 1993;82(4):1335-43.